Months after Scott Gottlieb stepped down from his role as commissioner of the U.S. Food and Drug Administration (FDA), he found himself back in the world of pharma as a member of Pfizer’s board of directors.
The former commissioner will certainly be a strong asset for that company with his knowledge of the regulatory landscape in the United States, as well as his insights into hot-button political issues such as drug pricing. Gottlieb was tapped to serve on two different board-level committees, the Regulatory and Compliance Committee and the Science and Technology Committee.
Pfizer Chief Executive Officer Albert Bourla said Gottlieb, who is also a physician, has a strong understanding of the needs of patients, as well the “rapidly changing dynamics of biopharmaceutical research and development.”
In an announcement on Twitter, Gottlieb said he was honored to be joining the board of directors at Pfizer and working with the company to “promote medical innovation, advance patient care and secure access to better healthcare outcomes for families around the world.”
“Gottlieb joins Pfizer as the company dives deeper into oncology, following its acquisition of Array BioPharma earlier this month, as well as its recent reorganization into three separate business units that include an established medicines business, a consumer healthcare business and the innovative medicines business.
During his two-year tenure at the FDA, Gottlieb aggressively supported the approval of new branded drugs, as well as generics. Additionally, he tackled multiple public health problems, including the opioid epidemic that has been sweeping the country and vaping. Gottlieb stepped down from his role at the FDA, in part, due to the travel commitments that kept him away from his young family.